Recombinant Human LILRB5/CD85c/LIR-8 Fc Chimera Protein, CF

When Recombinant Human LILRB5/CD85c/LIR-8 Fc Chimera (Catalog # 10410-T4) is immobilized at 0.5 μg/mL (100 μL/well), Recombinant Human Angiopoietin-like 7 (Catalog # 914-AN) binds with an ED50 of 0.03‑0.24 μg/mL.

2 μg/lane of Recombinant Human LILRB5/CD85c/LIR-8 Fc Chimera (Catalog # 10410-T4) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 85-105 kDa and 170-210 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human LILRB5/CD85c/LIR-8 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human LILRB5/CD85c/LIR-8 Fc Chimera (Catalog # 10410-T4) is immobilized at 0.5 µg/mL (100 µL/well), Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 (Catalog # 914-AN) binds with an ED₅₀ of 0.03-0.24 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human LILRB5/CD85c/LIR-8 protein
  

  Human LILRB5/CD85c/LIR-8 (Gly24-Gly458) Accession # O75023.1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: O75023.1
• N-terminal Sequence: Gly24
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 74 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 85-105 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human LILRB5/CD85c/LIR-8 Fc Chimera Protein, CF

• CD85 antigen-like family member C
• CD85c antigen
• CD85c
• Leukocyte immunoglobulin-like receptor 8
• leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains)
• LILRB5
• LIR8
• LIR-8
• LIR8CD85C
• LIR-8leukocyte immunoglobulin-like receptor subfamily B member 5
• member 5

Background

LIR8, also known as CD85c and LILRB5, belongs to the Leukocyte immunoglobulin-like receptors (LILR) family of transmembrane glycoproteins involved in regulating immune responses (1,2). There are at least thirteen LILR family members and are divided into activating (LILRA) or inhibiting (LILRB) molecules (1,2). Mature human LIR8 consists of an extracellular domain (ECD) with four Ig-like domains, a transmembrane segment, and a cytoplasmic domain with two immunoreceptor tyrosine-based inhibitory motifs (ITIM). Alternative splicing of human LIR8 generates at least 2 isoforms, one lacking the second Ig-like domain. The LILR family appears to be primate-specific receptors in terms of sequence homology. LIR8 is expressed on NK cells and in the tryptic granules of mast cells and negatively regulates immune cell activation (3, 4). It is present on the mast cell surface following cell activation and degranulation (4). Activated mast cells may also release soluble forms of LIR8 (3). LIR8 has also been shown to be expressed on T cells and induce CD8+ T cell proliferation (5).  Consistent with the demonstrated binding of LILRB2 to Angiopoietin-like 2 and 5 (6), R&D Systems in-house testing indicates that LIR8 binds to Angiopoietin-like 7. Recently, a common missense variant of LIR8 was found to be associated with statin intolerance and myalgia (7).

1. Brown, D. et al. (2004) Tissue antigens. 64:215.
2. Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
3. Borges, L. et al. (1997) J. Immunol. 159:5192.
4. Tedla, N. et al. (2008) J. Leukoc. Biol. 83:334.
5. Hogan, H. E. et al. (2016) Sci Rep. 6:21780.
6. Zheng, J. et al. (2012) Nature 485:656.
7. Siddigui, M. et al. (2017) Eur. Heart J. 38:3569.

Bioinformatics

• Uniprot:
  • O75023.1()